Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.
The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
The European Commission on Tuesday made public proposals that reverse an effective ban on sales of new internal combustion ...
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune ...
Gage survived, but unfortunately, it wasn't a total happy ending. His friends and doctor said that, post-accident, he was “no ...
In August, the corpses of four men were found along the banks of the river in Val-de-Marne, just outside Paris. Le Monde ...
Rezolute Inc.’s phase III Sunrize study of its only candidate, ersodetug, a fully human monoclonal antibody that binds to allosteric site on insulin receptors, missed its primary and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback